Mainstream medical literature now recognizes im-pact of genetics on patient response to drug therapy and the safety thereof…
PATIENT CARE IS NOW PERSONALIZED
Early Diagnosis is Important
Personalized Medicine is Here:
- The American Medical Association advises physicians to become familiar with genetic AMAX mutations that can affect patients’ drug metabolism, and be able to recognize when testing should be used to inform prescribing.
The U.S. Food and Drug Administration has issued numerous bulletins and updates to product labels informing clinicians and patients alike of these dan-gers, and how they can be assessed with genetic in-formation…
- The FDA currently recommends testing and is laying the groundwork for routine testing in early phase clinical drug trials in order to prevent the approval of danger-ous medication.
Dosing algorithms are available to account for genetic guidance for many drugs…
- A report from the U.S. Department of Health and Human Services states: “Pharmacogenetic testing for potential adverse drug events (ADEs) or ineffective drug responses may reduce health care costs over the long term by diminishing the duration and severity of illness and the costs associated with ineffective treat-ment and avoidable ADEs.”
The Time to Test is NOW!
© 2020 Global Diagnostic Laboratory. All rights reserved.